Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).L43797
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Efalizumab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Efalizumab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efalizumab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Efalizumab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efalizumab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Efalizumab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Efalizumab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Efalizumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efalizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Efalizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b. |
| Daclizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Flunisolide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bortezomib. |
| Cladribine | Efalizumab may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Amsacrine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Efalizumab is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Efalizumab is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Efalizumab is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Efalizumab is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Efalizumab is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Efalizumab is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Efalizumab is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Efalizumab is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Efalizumab is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Efalizumab is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Efalizumab is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Efalizumab is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Efalizumab is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Efalizumab is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Efalizumab is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Efalizumab is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Efalizumab is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Efalizumab is combined with Melphalan. |